Aurinia (Formerly Known as Isotechnika Pharma Inc.)
5120 - 75th Street
Edmonton
Alberta
T6E 6W2
Canada
Tel: 780-487-1600
Fax: 780-484-4105
Website: http://www.auriniapharma.com/
287 articles about Aurinia (Formerly Known as Isotechnika Pharma Inc.)
-
Aurinia To Present At The 2016 BIO Investor Forum In San Francisco On October 18, 2016
10/11/2016
-
Aurinia Releases Open-Label AURION Data Demonstrating Increased Remission Rates Over Time For Voclosporin In The Treatment Of Lupus Nephritis
10/6/2016
-
Aurinia Announces That Voclosporin Achieves Primary And All Pre-Specified Secondary Endpoints In Its Phase IIb AURA-LV Study For Lupus Nephritis (LN)
9/30/2016
-
Aurinia To Present At The Leerink Partners Roundtable Series In New York September 28, 2016
9/22/2016
-
Aurinia To Host Lupus Nephritis (LN) Breakfast And Webcast On September 30th In New York
9/21/2016
-
Aurinia To Present At The 2016 Rodman & Renshaw 18th Annual Global Investment Conference
9/7/2016
-
Aurinia's Voclosporin Meets Primary Endpoint in Phase IIB Aura-LV Study in Lupus Nephritis
8/15/2016
-
Aurinia Reports Second Quarter 2016 Financial Results And Operational Highlights
8/5/2016
-
Aurinia To Host Lupus Nephritis Expert Breakfast And Webcast On August 4th In New York
7/29/2016
-
Aurinia Establishes At-The-Market Facility
7/25/2016
-
Aurinia Announces 24 Week Remission Rates From The First Seven Patients In Its Open Label AURION Study In Lupus Nephritis (LN)
6/29/2016
-
Aurinia Announces Closing Of US$7 Million Private Placement
6/23/2016
-
Aurinia Announces Private Placement
6/15/2016
-
Aurinia Announces Results Of Annual General Meeting
6/10/2016
-
Aurinia Announces Presentations At The European Renal Association – European Dialysis And Transplant Association (ERA-EDTA) Meeting
5/13/2016
-
Aurinia Reports First Quarter 2016 Financial Results And Operational Highlights
5/12/2016
-
Aurinia Initiates First Clinical Study Of Voclosporin For Japan
5/9/2016
-
Aurinia To Present At The 2016 Bloom Burton & Co. Healthcare Investor Conference
4/28/2016
-
Aurinia Taps a New CEO
4/11/2016
-
Aurinia Announces Result From Data And Safety Monitoring Board For Its Phase 2b Study In Lupus Nephritis -- Study To Continue As Planned
3/29/2016